The U.S. Food and Drug Administration (FDA) on Tuesday approved Optune Pax®, a wearable medical device used in conjunction with chemotherapy, for the treatment of adult patients with locally advanced pancreatic cancer. This marks the first FDA approval of a modern treatment for this specific stage of the disease in nearly 30 years, according to the agency and Novocure, the device’s developer.
Optune Pax delivers Tumor Treating Fields (TTFields) therapy, utilizing alternating electric fields to disrupt cancer cell replication. The approval allows for its utilize alongside the standard chemotherapy combination of gemcitabine and nab-paclitaxel. The decision follows positive results from the Phase 3 PANOVA-3 clinical trial, which demonstrated a statistically significant improvement in overall survival for patients receiving TTFields in addition to chemotherapy.
According to trial data released in December 2024 and presented at the American Society of Clinical Oncology annual meeting in May 2025, patients treated with Optune Pax and chemotherapy lived an average of 16.2 months, compared to 14.2 months for those receiving chemotherapy alone. The trial also indicated a significant extension in the time patients experienced pain progression – six additional months – and improvements in quality of life measures, including digestive issues and fatigue.
“The approval of Optune Pax is an important milestone for the pancreatic cancer community,” stated Dr. Anna Berkenblit, Chief Scientific and Medical Officer at the Pancreatic Cancer Action Network (PanCAN), in a press release. “Survival rates for pancreatic cancer have seen only modest improvements over time and treatment advances have remained limited, underscoring how challenging this disease is to treat.”
The treatment is specifically approved for patients with unresectable, locally advanced pancreatic adenocarcinoma – meaning the cancer has not spread widely but is too advanced for surgical removal. Dr. Vincent Picozzi, a medical oncologist and investigator in the PANOVA-3 trial, described the trial as “the first-ever positive randomized trial for locally advanced disease” and expressed hope that it would serve as a foundation for future advancements.
Dr. Picozzi added that the treatment, in the clinical trial, improved overall survival “without adding to the systemic side effects commonly associated with existing therapies.” The most common side effect reported with Optune Pax is mild to moderate skin irritation under the device’s arrays, which may cause warming or tingling sensations.
The FDA stated that Optune Pax is designed to be worn with a generator carried in a specialized bag, allowing for continuous treatment during daily activities. TTFields therapy has previously been approved for glioblastoma and metastatic non-small cell lung cancer, functioning by disrupting cancer cell division without significantly impacting healthy cells.
While FDA approval typically leads to Medicare and Medicaid coverage, insurance coverage for Optune Pax will vary depending on individual plans. PanCAN Patient Services recommends that patients discuss this treatment option with their healthcare team and offers resources for clinical trial searches, specialist referrals, and financial assistance programs.
